Perfil clínico de pacientes com Hepatite Crônica C submetidos ao tratamento com novos antivirais de ação direta em serviços de referência de Salvador

Abstract

Title: Patients Clinical Profiles with Chronic Hepatitis C submitted to the treatment with new direct acting antiviral in reference services in Salvador. Introduction: Chronic Hepatitis C has a high global prevalence and the main objective of your treatment is to obtain the sustained virological response (SVR). In the last years, new drugs are being used to the treatment of Cronic Hepatitis C: the new direct acting antiviral (DAA), that enable a more effective treatment with fewer adverse effects. Objective: The main objective of this study is to know the clinical profile of the population monitored in references services with diagnosis of Chronic Hepatitis C. Methodology: This study is descriptive and cross-sectional type, and has a population composed of patients with diagnosis of Chronic Hepatitis C treated in viral hepatites ambulatory, in references services in Salvador-BA. The variables were collected through the fill of the clinical file with informations obtained in medical records and interview with patients. The statistical analysis was based on the calculation of means, medians, standards deviations and simple frequency. Results: The population of this study is composed by 74 patients, with mean (standard deviation) age of 60,3 (+/-10) years, and 79,7% of patients were genotype 1, while 20,3% were genotype 3. Only 36 patients had documented in the medical records grade of hepatic fibrosis (metavir), among them, 27,8% were F4, 27,8% were F3, 25% were F2 e 19,4% were F1. All patients at the study made use of the new DAA, and 97% achieved a SVR of 12 weeks after treatment, while 3% presented therapeutic failure. Discussion: Clinical-demographic characteristics such as age, ethnicity and presence of comorbidities, as well the percentage of SVR, described in the present study, approximate those observed by other studies that have a population formed by HCV patients treated in ambulatory. Conclusions: The present study, limited by the total number of patients, described a clinical-demographic profile similar to other studies. It also described several risk factors for HCV contamination, including sharp and cutting materials sharing. Lastly, the percentage of SVR achieved after the treatment with the new DAA in this study, is similar that found in the literature.